Biogen Loses Bid to Block Rival’s Multiple Sclerosis Drug (1)

Feb. 27, 2020, 7:56 PMUpdated: Feb. 27, 2020, 10:23 PM

Biogen International GmbH failed to convince the Federal Circuit to stop Banner Life Sciences from selling its multiple sclerosis drug while appealing a lower court patent ruling.

Biogen failed to establish that an injunction against Banner’s Bafiertam is warranted even though it causes the same chemical reaction in the body when an active ingredient is consumed as that created by Biogen’s Tecfidera, the U.S. Court of Appeals for the Federal Circuit said Thursday.

The case spotlights the issue of whether patent-term extensions, given to drugmakers to compensate for delays in obtaining Food and Drug Administration approval, apply only to a ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.